What Sanofi does

Sanofi is a global biopharmaceutical company headquartered in Paris, France, that develops and commercializes prescription medicines, vaccines, and consumer healthcare products across five therapeutic areas: Immunology, Neurology, Oncology, Rare Diseases, and Vaccines. Founded in 1973 with heritage dating to the 19th century, the company operates in 70+ countries (with business activity in 100+ markets) and employs more than 83,000 people globally. Its portfolio spans blockbuster franchises — most notably Dupixent (€4.2B in Q1 2026 sales, co-developed with Regeneron), Beyfortus (anti-RSV, $2B+ annual sales, with AstraZeneca), Sarclisa (oncology), Tzield (first disease-modifying T1D therapy), and a vaccines franchise delivering 1.3 million doses daily — alongside a consumer healthcare business operated through standalone subsidiary Opella.

The company's R&D engine is built around an "immunoscience" platform combining deep immunological expertise with proprietary technology platforms including NANOBODY® molecules, TAILORED COVALENCY™ chemistry, mRNA, multi-specific antibodies, NK cell engagers, targeted protein degradation, siRNA conjugates, antibody-drug conjugates, and genomic medicine, all integrated with AI and computational technologies. Sanofi reports 77 clinical-stage projects with 28 in Phase 3, supported by a $294M Toronto AI center, Owkin K Pro agentic AI deployment, Snowflake/Elementum enterprise data unification, and a stated goal of becoming "the first biopharma company powered by AI at scale."

Sanofi generates revenue through direct prescription drug sales, vaccine distribution via global manufacturing and supply networks, profit-share collaborations (e.g., Regeneron for Dupixent), licensing royalties, and consumer healthcare products. The business model combines enterprise sales to HCPs and healthcare systems in mature markets, government tenders (NHS, NICE-approved products), humanitarian distribution through its Global Health Unit in 40 underserved countries, and consumer healthcare through Opella. Capital deployment is aggressive: ~$30B in M&A since 2020 (Bioverativ $11.6B, Blueprint Medicines $6.3B, Translate Bio $3.2B, Provention Bio $2.9B, Dynavax $2.2B), supplemented by a $3B bond issuance in October 2025 to fund further pipeline replenishment.

Name

Sanofi

Legal name

Sanofi S.A.

Website

https://sanofi.com

Company type

Public

Founded year

1973

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sanofi is a global biopharmaceutical company that develops and commercializes prescription medicines, vaccines, and consumer healthcare products across immunology, neurology, oncology, rare diseases, and vaccines, serving patients and healthcare systems in 100+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Prescription pharmaceuticals
• Vaccine development
• Biopharmaceutical research
• Immunology therapies
• Rare disease treatments

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Specialty Care & General Medicines): Sales of prescription medicines across Sanofi's therapeutic areas (Immunology, Neurology, Oncology, Rare Diseases) including blockbuster products Dupixent, Sarclisa, and Tzield. Includes both IV and subcutaneous formulations.
2. Vaccines Sales: Sales of Sanofi's portfolio of vaccines including influenza, polio, meningitis, rabies, and RSV (Beyfortus with AstraZeneca) — protecting half a billion people worldwide and delivering 1.3 million vaccine doses daily.
3. Profit-Share Collaboration (Dupixent with Regeneron): Collaboration profit-share arrangement with Regeneron for Dupixent, which generated €4.2 billion in Q1 2026 sales (30.8% growth). Regeneron's profit share grew 42% in the most recent quarter.
4. Licensing Royalties & Milestone Payments: Sanofi receives milestone payments and royalties (e.g., $24.5M milestone from Sanofi to MacroGenics for TZIELD approval; $20M milestone from Sanofi to Kymera for KT-485 Phase 1 trial commencement) and pays milestone/royalty obligations to licensors.
5. Consumer Healthcare (Opella) Sales: Consumer healthcare products (vitamin, mineral, and supplements) including Qunol brand (CoQ10 and Turmeric) — operated through Opella, the standalone consumer healthcare entity.
6. M&A-Driven Pipeline Expansion: Strategic acquisitions to expand portfolio: Provention Bio ($2.9B, 2023), Translate Bio ($3.2B, 2021), Kadmon ($1.9B, 2021), Amunix Pharmaceuticals (~$1B, 2021), Dynavax (~$2.2B, 2026), Vicebio (2025), Inhibrx, Blueprint Medicines, Principia Biopharma ($3.7B, 2020), Bioverativ ($11.6B, 2018).

Pricing tiers

Go-to-market motion5 records

Distribution channels10 records

Core offering

Sanofi is a global biopharmaceutical company that researches, develops, manufactures, and commercializes prescription medicines and vaccines across five therapeutic areas: Immunology, Vaccines, Neurology, Oncology, and Rare Diseases. Its commercial portfolio includes blockbuster drugs such as Dupixent (dupilumab, co-developed with Regeneron), Sarclisa (isatuximab) for multiple myeloma, Tzield (teplizumab) for type 1 diabetes, Beyfortus (nirsevimab, with AstraZeneca) for RSV, and a broad vaccine portfolio protecting half a billion people worldwide. The company also operates a Consumer Healthcare business (Opella) and a Global Health Unit providing access to essential medicines in 40 underserved countries.

Differentiator

Problem solved

Functional benefit

Brands

• Opella: Sanofi's Consumer Healthcare business offering non-prescription medicines and self-care products, operated as a distinct entity under the Sanofi corporate umbrella.
• Sanofi Foundation (Fondation Sanofi)
• Foundation S
• Impact
• Sanofi Consumer Healthcare India
• Sanofi India

Products and services

• Dupixent (dupilumab) Dupixent (dupilumab) is a prescription biologic co-developed and commercialized with Regeneron for type 2 inflammatory diseases including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and chronic spontaneous urticaria; sold to healthcare professionals and healthcare systems globally.
• Sarclisa (isatuximab) IV and Subcutaneous Sarclisa (isatuximab) is an anti-CD38 antibody for multiple myeloma, available in both intravenous and subcutaneous formulations; subcutaneous form is delivered via the CirCLIQ on-body injector and reduces infusion reactions from 25% to 1.5% versus the IV formulation.
• Tzield (teplizumab) Tzield (teplizumab-mzwv) is the first disease-modifying therapy for type 1 diabetes, delaying the decline of endogenous insulin production in pediatric and adult patients recently diagnosed with stage 3 T1D and delaying onset of stage 3 in stage 2 patients.
• Beyfortus (nirsevimab) Beyfortus (nirsevimab) is an extended half-life anti-RSV monoclonal antibody for passive immunization of newborns and high-risk children against RSV, co-developed by AstraZeneca and sold by Sanofi, achieving over $2 billion in annual sales since launch.
• Sanofi Vaccine Portfolio (Influenza, Polio, Meningitis, Rabies, etc.)

Quantifiable outcome

• €4.2 billion in Dupixent Q1 2026 sales, representing 30.8% growth
• +13 more outcomes

Named customers16 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability6 records

Feature11 records

Partnerships

29 partnerships are on record, tiered minor, major and flagship.

• Cerebral Palsy FoundationminorGTM or Marketing Partner · 25 June 2026The Sanofi Foundation announced partnerships with the Cerebral Palsy Foundation (early diagnosis for nearly 1,000 children) and AIDA (support for up to 1,600 young people during and after hospitalization). The Foundation has a goal of positively impacting more than 6 million children and young people by 2030.
• Department of Health - Abu DhabimajorStrategic or Co-development Partner · 22 June 2026Memorandum of Understanding signed during the BIO International Convention 2026 in San Diego to establish a Vaccine Innovation Centre in Abu Dhabi. The partnership will leverage AI-powered vaccine research, mRNA research, clinical development, and advanced manufacturing capabilities within Abu Dhabi's HELM cluster (Health, Endurance, Longevity, and Medicine). The collaboration aims to strengthen regional and global health preparedness while fostering local scientific talent and next-generation vaccine innovation.
• HEC ParisminorGTM or Marketing Partner · 19 June 2026Sanofi and HEC Paris launched the 'Sanofi MBA Life Sciences Scholarship' — a scholarship program offering 10 annual scholarships covering 75% of tuition fees for the HEC Paris MBA. The program targets candidates from scientific and medical backgrounds to develop dual expertise at the intersection of health and business management.
• COUR PharmaminorStrategic or Co-development Partner · 18 June 2026COUR Pharma closed a $50 million Series B funding round with participation from Sanofi to advance CNP-103, an investigational antigen-specific immune tolerance therapy for type 1 diabetes that aims to prevent islet cell destruction by reprogramming inflammatory autoimmune responses. The funding will support continued development of the therapy.
• IQVIAminorStrategic or Co-development Partner · 18 June 2026Sanofi developed a whitepaper in collaboration with IQVIA, demonstrating how it addresses global health challenges through a collaborative and systematic data-driven approach. The work uses Sanofi's innovative Global Health Needs Tool to identify where action is most urgently needed.
• Eli LillyminorOthers · 15 June 2026Sanofi (along with Regeneron, Novartis, Amgen, AstraZeneca, GSK) was named as a co-defendant in a whistleblower lawsuit accusing Genentech and Novartis of orchestrating a kickback scheme for Xolair since 2003. The lawsuit seeks trebled damages under the False Claims Act.
• SnowflakemajorTechnology or Integration · 11 June 2026Sanofi unified its data on Snowflake and partnered with Elementum to build agentic workflows supporting R&D, manufacturing, commercial operations, procurement, IT support, HR, and sales. This includes an AI agent called 'Concierge for Field' that prepares sales representatives for physician visits. Sanofi was featured as a leading case study at Snowflake's 2026 summit.
• OwkinmajorStrategic or Co-development Partner · 8 June 2026Multi-year agreement with Owkin, including a five-year licence for Owkin's K Pro AI scientist platform to co-develop next-generation AI-driven biopharma agents. The partnership builds on existing €90m collaboration since 2021 focused on oncology target identification, which expanded to immunology drug positioning, and now marks a shift toward comprehensive AI integration across Sanofi's biopharma workflows. Owkin will oversee end-to-end construction of agentic AI tools deployed through K Pro.
• Boston 26 (2026 FIFA World Cup)majorGTM or Marketing Partner · 1 January 2026Sanofi signed a host-city partnership with Boston 26 for the 2026 FIFA World Cup. The company is leveraging its 900,000-square-foot Massachusetts campus. The event is being held across the US, Canada, and Mexico with an expected global audience of six billion people.
• Earendil LabsminorStrategic or Co-development Partner · 1 January 2026Sanofi announced a $1.7 billion deal with Earendil Labs as part of Western pharmaceutical companies' multi-billion dollar partnerships with AI biotech firms.
• Dynavax Technologies CorporationmajorStrategic or Co-development Partner · 24 December 2025Sanofi completed the acquisition of Dynavax Technologies Corporation on February 10, 2026, through a merger following a tender offer. The deal included Dynavax's hepatitis B and shingles vaccines, expanding Sanofi's presence in adult immunization. Dynavax shareholders received $15.50 per share in cash. The deal was valued at approximately $2.2 billion.
• VicebiominorStrategic or Co-development Partner · 4 December 2025Sanofi completed its acquisition of Vicebio as part of its broader expansion strategy in the pharmaceutical sector. Transaction details and strategic implications are not specified in the article.
• Nurix TherapeuticsminorStrategic or Co-development Partner · 1 January 2025Sanofi extended its license option for Nurix's STAT6 program. The deal is part of a broader $2.3 billion collaboration deal that Roche also entered with Nurix. Nurix's lead candidate bexobrutideg has entered a pivotal Phase 2 study.
• QunolmajorStrategic or Co-development Partner · 29 September 2023Sanofi completed the acquisition of Qunol, a U.S.-based health and wellness brand, to strengthen its Consumer Healthcare division (Opella). The acquisition focuses on the growing vitamin, mineral, and supplements sector in the U.S. and includes Qunol's CoQ10 and Turmeric products, aimed at heart and joint health respectively.
• Provention Bio, Inc.majorStrategic or Co-development Partner · 27 April 2023Sanofi completed the acquisition of Provention Bio, Inc. on April 27, 2023, through a merger following a tender offer, adding TZIELD (teplizumab) — a first-in-class therapy for type 1 diabetes — to its portfolio. The transaction involved a cash payment of $25.00 per share for all tendered shares. The deal was valued at approximately $2.9 billion.
• AstraZenecaflagshipStrategic or Co-development Partner · 1 January 2023Co-development of Beyfortus (nirsevimab), an extended half-life anti-RSV monoclonal antibody developed by AstraZeneca and sold by Sanofi. Beyfortus has achieved over $2 billion in annual sales since its launch in Fall 2023, demonstrating strong demand for passive immunization products in newborns and high-risk children.
• Blackstone Life SciencesmajorStrategic or Co-development Partner · 15 March 2022€300 million financing collaboration with Sanofi to develop a subcutaneous formulation of the anti-CD38 antibody Sarclisa® for multiple myeloma. The collaboration aims to accelerate clinical trials and offers potential future royalties to Blackstone if successful, while Sanofi partners with Enable Injections to develop the delivery method. A pivotal study was expected to start in late 2022. Blackstone is also a financial partner providing the development capital.
• Amunix PharmaceuticalsmajorStrategic or Co-development Partner · 21 December 2021Sanofi acquired Amunix Pharmaceuticals, an immuno-oncology company, for approximately $1 billion with additional milestone payments totaling up to $225 million. The acquisition brings next-generation biologics technology, including a pipeline of preclinical oncology T-cell engagers with the lead candidate AMX-818, to enhance Sanofi's cancer treatment portfolio.
• Origimm Biotechnology GmbHminorStrategic or Co-development Partner · 1 December 2021Sanofi acquired Origimm Biotechnology GmbH, an Austrian biotech firm specializing in skin microbiome antigens, as part of its strategy to expand its vaccine pipeline. The deal includes a vaccine candidate for acne vulgaris (ORI-001), which has entered preliminary clinical studies, with plans to leverage Sanofi's mRNA platform for further development.
• Translate BiomajorStrategic or Co-development Partner · 14 September 2021Sanofi completed its acquisition of Translate Bio for $3.2 billion in cash, expanding its mRNA technology capabilities for vaccines and therapies. The transaction included a cash payment of $38 per share. This strategic move aims to enhance Sanofi's pipeline in immunology, oncology, and rare diseases.
• Regeneron PharmaceuticalsflagshipStrategic or Co-development PartnerLong-standing collaboration with Regeneron for the co-development and commercialization of Dupixent (dupilumab). Regeneron reported 42% growth in its share of profits from the Sanofi collaboration in the most recent quarter, with global net sales of Dupixent jumping 31%. The two companies also study how blocking two interleukins can help calm type 2 inflammation in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Regeneron's expected to capture its full share of collaboration profits once the development cost repayment balance to Sanofi is fully paid off by mid-year.
• Enable InjectionsmajorTechnology or IntegrationSanofi partners with Enable Injections for the development of the enFuse® and CirCLIQ® on-body injector for subcutaneous delivery of Sarclisa (isatuximab). Sarclisa SC was approved in the EU and Japan as the first anticancer treatment administered via a portable on-body injector, with 70% patient satisfaction with the on-body injector vs 53.4% for manual injection. A regulatory submission for CirCLIQ is also under review in Japan.
• Kymera TherapeuticsmajorStrategic or Co-development PartnerCollaboration agreement under which Kymera received a $20 million milestone payment from Sanofi for the commencement of a Phase 1 clinical trial of KT-485 (SAR447971), an oral IRAK4 degrader developed under the collaboration. The trial enrolls healthy volunteers and hidradenitis suppurativa patients. Kymera is eligible for up to $975 million in total development and commercialization milestones under the deal. The program targets inflammatory skin disease.
• My Green LabminorStrategic or Co-development PartnerSanofi joined forces with My Green Lab — the world's leading sustainability certification program for laboratories — to make research spaces more sustainable and more efficient. Through this partnership, Sanofi is joining a global community embedding environmental responsibility into every stage of the scientific process.
• Pharmaceutical Supply Chain Initiative (PSCI)minorOthersSanofi is an active member of the Pharmaceutical Supply Chain Initiative (PSCI), which aims to improve supplier practices through common standards, support, training, and audits. This helps Sanofi deliver on its commitments to society.
• Sustainable Markets Initiative (SMI) Health Systems Task ForcemajorOthersSanofi is actively involved in the Sustainable Market Initiative healthcare system taskforce to accelerate the delivery of net zero, sustainable healthcare. Sanofi is leading the 'Patient care pathway decarbonization' working group and leads the Pharma LCA Consortium via the Pharmaceutical Environment Group (PEG).
• IntraCare / CareOnminorImplementation/ SI/ Consulting PartnerIntraCare (now CareOn) contributed to Sanofi's ATLAS clinical trials, which helped the United States rank among the top ten countries for meeting participant recruitment goals. CareOn currently operates two research sites in Dallas and Greenville, Texas.
• Blueprint MedicinesmajorStrategic or Co-development PartnerSanofi acquired Blueprint Medicines (referenced as part of Sanofi's portfolio alongside Provention Bio, Inhibrx, and Dynavax). Blueprint Medicines' avapritinib (Ayvakit/Ayvakyt) is now part of Sanofi, with new data from the PIONEER study showing quality-of-life gains in indolent systemic mastocytosis.
• Regeneron PharmaceuticalsflagshipStrategic or Co-development PartnerSanofi's regulatory engagement with the FDA is also noted in the context of the Commissioner's National Priority Voucher (CNPV) program, where Sanofi reportedly requested to withdraw Tzield from the program after reported interference from former acting CDER director Tracy Beth Høeg, before later receiving expanded approval.

Scale indicators25 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pfizer: Pfizer is one of Sanofi's closest direct peers — a global biopharmaceutical company with major vaccines (Comirnaty, Prevnar) and specialty care franchises (oncology, inflammation, rare disease). Comparable in scale, therapeutic breadth, and vaccine/biologics R&D focus.
• Merck & Co. (MSD): Merck is a directly comparable global biopharma peer with a leading vaccines franchise (Gardasil) and blockbuster specialty pharma (Keytruda oncology, immunology). Comparable in R&D depth, oncology/immunology focus, and vaccines footprint.
• GlaxoSmithKline (GSK): GSK is a direct vaccines competitor (Shingrix, Bexsero) with parallel specialty pharma and consumer healthcare operations. Closely comparable to Sanofi across vaccines R&D, immunology, and OTC/consumer health via Haleon-style structure.
• Novartis: Novartis is a directly comparable specialty biopharma peer, with overlapping immunology, oncology, and rare disease franchises. Co-defendant with Sanofi in the Xolair whistleblower lawsuit, reflecting similar immunology portfolios.
• Roche: Roche is a directly comparable global biopharma peer with leading oncology, immunology, and diagnostics franchises. Paulo Fontoura (Sanofi's incoming R&D head) spent 15+ years at Roche, reflecting deep talent and portfolio overlap.
• AstraZeneca: AstraZeneca is both a direct peer and a key Sanofi partner (Beyfortus anti-RSV). Comparable in oncology, immunology, vaccines/biologics R&D, and global commercial scale. Co-defendant in the whistleblower lawsuit alongside Sanofi.
• Eli Lilly: Eli Lilly is a directly comparable specialty biopharma peer with overlapping immunology, oncology, and rare disease franchises. Named alongside Sanofi as a co-defendant in the Xolair whistleblower lawsuit, and a leader in immunology/inflammation R&D.
• AbbVie: AbbVie is a directly comparable immunology-heavy biopharma peer (Humira/Skyrizi/Rinvoq franchise) with parallel oncology, neurology, and aesthetics operations. Highly relevant comparable given shared immunology focus with Dupixent.
• Bristol-Myers Squibb: BMS is a directly comparable global biopharma peer with leading oncology and immunology franchises (Opdivo, Yervoy, Zeposia, deucravacitinib). Overlapping therapeutic area focus in immunology and oncology makes BMS a relevant specialty-pharma comparable.

Broad incumbents

• Johnson & Johnson (Innovative Medicine): J&J is a broader incumbent with overlapping immunology (Tremfya, Stelara), oncology, and rare disease franchises, plus vaccines via its historical Janssen portfolio. Comparable as a major diversified biopharma but with a broader medical devices footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/sanofi
• YouTubeyoutube.com/sanofi
• Facebookfacebook.com/Sanofi
• LinkedInlinkedin.com/company/sanofi
• Instagraminstagram.com/sanofi

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries12 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A34 records

Investments65 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi